AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

HRMY · NASDAQ · Biotechnology

Harmony Biosciences (HRMY)

Commercializes WAKIX for narcolepsy while developing next-generation pitolisant and rare-neurology therapies.

$40.11

vs last close−1.42 (−3.42%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	160	168	155	173	186	201	185	200	239	244	215	261
Cost of revenue	32	43	27	32	43	54	32	38	60	69	45	63
Gross profit	128	125	127	141	143	147	153	162	180	175	171	198
	63	85	75	119	82	91	96	114	114	137	134	109
Research & development	17	30	22	64	25	35	35	50	55	50	69	47
	46	55	53	56	56	56	62	64	59	87	64	62
Selling & marketing	23	27	27	29	28	28	31	30	30	29	32	34
General & administrative	23	28	26	27	29	29	31	34	30	58	33	28
Operating income	65	40	52	21	62	56	56	48	65	39	37	89
	−13	−1	0	0	0	0	1	1	2	2	2	4
Interest income	4	4	4	5	5	4	5	5	6	6	6	7
Interest expense	7	5	5	4	4	4	4	4	4	4	3	3
Other non-operating income	6	−15	−4	−5	−5	−5	−5	−5	−2	−6	−6	−7
Income before tax	52	40	52	22	62	56	57	50	67	41	40	93
Income tax expense	13	13	13	10	16	7	12	10	17	18	7	18
Net income from continuing operations	38	27	38	12	46	49	46	40	51	22	32	75
Net income	38	27	38	12	46	49	46	40	51	22	32	75
EPS, basic	$0.64	$0.46	$0.68	$0.20	$0.81	$0.87	$0.80	$0.69	$0.88	$0.39	$0.56	$1.30
EPS, diluted	$0.63	$0.45	$0.67	$0.20	$0.79	$0.85	$0.78	$0.68	$0.87	$0.38	$0.55	$1.28
Weighted average shares, basic	60	58	57	57	57	57	57	57	58	58	58	58
Weighted average shares, diluted	61	59	58	58	58	58	59	58	59	59	59	59
EBITDA	65	61	62	32	72	66	67	59	73	52	49	102
Depreciation & amortization	6	6	6	6	6	6	6	6	6	7	6	6
EBIT	59	55	56	26	67	60	61	53	67	44	43	96